스마트 인슐린 투여 기기 시장 : 시장 예측 - 디바이스 유형별, 기술별, 투여 메커니즘별, 구성부품별, 접속 방식별, 환자층별, 유통 채널별, 용도별, 최종 사용자별 및 지역별 분석(-2034년)

According to Stratistics MRC, the Global Smart Insulin Delivery Devices Market is accounted for $1.1 billion in 2026 and is expected to reach $2.7 billion by 2034 growing at a CAGR of 11.8% during the forecast period. The smart insulin delivery devices market is witnessing significant transformation with the integration of intelligent features that support efficient diabetes care. Modern solutions combine automated insulin administration, glucose tracking, and wireless connectivity to provide users with better control and improved outcomes. Increasing diabetes cases, technological advancements, and preference for personalized healthcare are accelerating adoption. These systems offer enhanced convenience, continuous monitoring, and data-driven insights for patients and providers. Developments in artificial intelligence, sensors, and digital platforms are strengthening product capabilities, making smart insulin delivery devices an important component of future diabetes management strategies across global healthcare environments and clinical practices.

Market Dynamics:

Driver:

Increasing Adoption of Connected Healthcare Technologies

Rising utilization of digital healthcare solutions is accelerating demand for smart insulin delivery devices with advanced connectivity features. These systems can connect with mobile devices, cloud-based platforms, and healthcare applications to support continuous data exchange and remote diabetes management. Such capabilities help doctors monitor patient progress and optimize insulin therapy based on real-time information. Enhanced accessibility, improved patient involvement, and personalized care options are increasing the acceptance of connected insulin technologies. The expansion of virtual healthcare services and digital transformation initiatives within healthcare systems are further strengthening market opportunities. Consequently, connected smart insulin delivery solutions are becoming increasingly valuable for modern diabetes management.

Restraint:

High Cost of Smart Insulin Delivery Devices

Expensive smart insulin delivery systems represent a significant challenge for broader market adoption, especially in developing and cost-conscious economies. The integration of advanced components such as automated pumps, monitoring sensors, digital connectivity, and intelligent control systems increases the overall price of these devices. Limited reimbursement policies and inadequate insurance support can prevent many patients from accessing these technologies. Healthcare organizations with restricted budgets may also delay implementation due to high acquisition costs. Despite their advantages in improving diabetes control, the substantial upfront expense continues to affect affordability. This cost barrier may reduce adoption rates and limit market expansion in several regions worldwide.

Opportunity:

Development of Wearable and Miniaturized Insulin Delivery Devices

Innovations in wearable and compact insulin delivery technologies are creating significant opportunities for the expansion of the smart insulin devices market. Improvements in sensors, electronics, and device engineering are helping manufacturers develop smaller, lightweight, and more comfortable solutions. These advanced systems enable continuous glucose monitoring and automated insulin delivery while allowing users to maintain normal daily activities. Companies are investing in better designs, longer-lasting power systems, and stronger connectivity features to improve patient experience. Growing interest in minimally invasive medical technologies is accelerating adoption. With increasing demand for convenient diabetes management options, wearable smart insulin delivery devices are expected to achieve greater market acceptance.

Threat:

Intense Competition from Alternative Diabetes Management Technologies

Growing competition from other diabetes treatment technologies creates challenges for the expansion of the smart insulin delivery devices market. Alternative solutions, including conventional insulin delivery methods, continuous monitoring systems, medications, and developing non-invasive approaches, may limit adoption of smart insulin technologies. Many users continue choosing traditional options because they are more affordable, widely available, and familiar. Advancements in competing products could further impact demand by offering similar therapeutic advantages. To remain competitive, manufacturers need to focus on improving affordability, functionality, and user experience. Continuous innovation will be essential to differentiate smart insulin delivery systems and sustain their position in the evolving diabetes management market.

Covid-19 Impact:

The COVID-19 pandemic influenced the smart insulin delivery devices market by creating both challenges and growth opportunities. Early pandemic conditions affected manufacturing operations, supply networks, and routine healthcare access, causing delays in device availability and patient support services. However, reduced hospital visits and increased reliance on remote healthcare encouraged greater adoption of connected insulin management technologies. Telehealth expansion enabled healthcare professionals to monitor diabetes patients and provide treatment guidance from a distance. The pandemic emphasized the value of continuous monitoring and automated insulin solutions for chronic disease management. Following recovery, rising digital healthcare adoption and remote monitoring trends supported further market expansion.

The Smart Insulin Pumps segment is expected to be the largest during the forecast period

The Smart Insulin Pumps segment is expected to account for the largest market share during the forecast period, driven by the growing preference for intelligent insulin management technologies that enable accurate and automated insulin delivery. These devices provide better control over glucose levels through continuous administration, digital connectivity, and integration with monitoring systems. Increasing focus on personalized healthcare, rising diabetes prevalence, and demand for convenient treatment options are contributing to wider acceptance of smart insulin pumps. Their advantages, including reduced user effort, improved therapy management, and enhanced patient experience, make them a leading solution within the smart insulin delivery devices market.

The Data Analytics and Decision Support Software segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Data Analytics and Decision Support Software segment is predicted to witness the highest growth rate, supported by the rising need for advanced digital tools that improve diabetes care through data-driven insights. These solutions evaluate glucose trends, insulin patterns, and patient-specific information to deliver personalized recommendations and enhance treatment efficiency. Increasing adoption of artificial intelligence, machine learning algorithms, and cloud-enabled healthcare platforms is further promoting segment growth. The growing emphasis on predictive healthcare, remote monitoring, and personalized diabetes management is encouraging the use of analytics-based solutions. These capabilities are strengthening the role of decision support software within smart insulin delivery ecosystems.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by increasing diabetes prevalence, advanced healthcare facilities, and early adoption of innovative medical solutions. The region has strong market growth potential due to greater awareness of intelligent insulin management systems, established reimbursement frameworks, and the presence of major industry participants. Rising adoption of connected medical technologies, integration with glucose monitoring platforms, and growing focus on personalized diabetes care are driving demand. Furthermore, increased investments in digital healthcare infrastructure and remote monitoring solutions are contributing to the widespread acceptance and expansion of smart insulin delivery devices throughout the North American region.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by increasing diabetes cases, healthcare modernization, and rising acceptance of innovative treatment solutions. The region is witnessing greater demand for intelligent insulin management technologies as healthcare providers and patients become more aware of digital and personalized diabetes care approaches. Growth is further supported by rising healthcare expenditure, government programs focused on disease management, and improved availability of advanced medical technologies. Furthermore, expanding smartphone usage, telemedicine adoption, and remote healthcare monitoring capabilities are creating favorable conditions for the rapid adoption of smart insulin delivery devices throughout Asia-Pacific markets.

Key players in the market

Some of the key players in Smart Insulin Delivery Devices Market include Medtronic plc, Insulet Corporation, Tandem Diabetes Care, Inc., Dexcom, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd., Ypsomed Holding AG, EOFlow Co., Ltd., Bigfoot Biomedical, Inc., Beta Bionics, Inc., SOOIL Development Co., Ltd., ViCentra B.V., Medtronic Diabetes, Cellnovo Group SA (historical/legacy player), Diabeloop S.A.S., CamDiab Ltd., A. Menarini Diagnostics S.r.l. and Nipro Corporation.

Key Developments:

In July 2026, Insulet announced a partnership with Calm to provide mindfulness and emotional well-being resources for people living with diabetes, caregivers, and healthcare professionals.

In January 2026, Diabeloop announced a collaboration with Sequel Med Tech to integrate its FDA-cleared DBLG2 automated glycemic control algorithm into Sequel's twiist(TM) Automated Insulin Delivery (AID) system.

In December 2025, Roche Diagnostics highlighted its continued partnership-driven approach in diabetes care, including collaborations supporting access to continuous glucose monitoring (CGM) technologies and integrated diabetes management solutions.

Device Types Covered:

• Smart Insulin Pens
• Smart Insulin Pumps
• Smart Insulin Patch Pumps
• Automated Insulin Delivery Systems
• Connected Insulin Delivery Devices

Technologies Covered:

• Continuous Glucose Monitoring (CGM) Integration
• Closed-Loop Insulin Delivery Technology
• Artificial Intelligence (AI)-Based Insulin Management
• Predictive Insulin Delivery Algorithms
• Remote Monitoring Technology

Delivery Mechanisms Covered:

• Continuous Subcutaneous Insulin Infusion (CSII)
• Smart Pen-Based Insulin Injection
• Patch-Based Insulin Delivery

Components Covered:

• Insulin Delivery Devices
• Sensors and Monitoring Components
• Connectivity Modules
• Mobile Applications
• Cloud-Based Software Platforms
• Data Analytics and Decision Support Software

Connectivity Types Covered:

• Bluetooth Connectivity
• Wi-Fi Connectivity
• Cellular Connectivity
• Near Field Communication (NFC)

Patient Types Covered:

• Pediatric Patients
• Adult Patients
• Geriatric Patients

Distribution Channels Covered:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Direct-to-Consumer Channels

Applications Covered:

• Type 1 Diabetes Management
• Type 2 Diabetes Management
• Gestational Diabetes Management

End Users Covered:

• Hospitals and Clinics
• Diabetes Care Centers
• Home Healthcare Settings
• Ambulatory Care Centers

Regions Covered:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Netherlands
  • Belgium
  • Sweden
  • Switzerland
  • Poland
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Malaysia
  • Singapore
  • Vietnam
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Colombia
  • Chile
  • Peru
  • Rest of South America
• Rest of the World (RoW)
  • Middle East
• Saudi Arabia
• United Arab Emirates
• Qatar
• Israel
• Rest of Middle East
  • Africa
• South Africa
• Egypt
• Morocco
• Rest of Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

• 1.1 Market Snapshot and Key Highlights
• 1.2 Growth Drivers, Challenges, and Opportunities
• 1.3 Competitive Landscape Overview
• 1.4 Strategic Insights and Recommendations

2 Research Framework

• 2.1 Study Objectives and Scope
• 2.2 Stakeholder Analysis
• 2.3 Research Assumptions and Limitations
• 2.4 Research Methodology
  • 2.4.1 Data Collection (Primary and Secondary)
  • 2.4.2 Data Modeling and Estimation Techniques
  • 2.4.3 Data Validation and Triangulation
  • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

• 3.1 Market Definition and Structure
• 3.2 Key Market Drivers
• 3.3 Market Restraints and Challenges
• 3.4 Growth Opportunities and Investment Hotspots
• 3.5 Industry Threats and Risk Assessment
• 3.6 Technology and Innovation Landscape
• 3.7 Emerging and High-Growth Markets
• 3.8 Regulatory and Policy Environment
• 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

• 4.1 Porter's Five Forces Analysis
  • 4.1.1 Supplier Bargaining Power
  • 4.1.2 Buyer Bargaining Power
  • 4.1.3 Threat of Substitutes
  • 4.1.4 Threat of New Entrants
  • 4.1.5 Competitive Rivalry
• 4.2 Market Share Analysis of Key Players
• 4.3 Product Benchmarking and Performance Comparison

5 Global Smart Insulin Delivery Devices Market, By Device Type

• 5.1 Smart Insulin Pens
• 5.2 Smart Insulin Pumps
• 5.3 Smart Insulin Patch Pumps
• 5.4 Automated Insulin Delivery Systems
• 5.5 Connected Insulin Delivery Devices

6 Global Smart Insulin Delivery Devices Market, By Technology

• 6.1 Continuous Glucose Monitoring (CGM) Integration
• 6.2 Closed-Loop Insulin Delivery Technology
• 6.3 Artificial Intelligence (AI)-Based Insulin Management
• 6.4 Predictive Insulin Delivery Algorithms
• 6.5 Remote Monitoring Technology

7 Global Smart Insulin Delivery Devices Market, By Delivery Mechanism

• 7.1 Continuous Subcutaneous Insulin Infusion (CSII)
• 7.2 Smart Pen-Based Insulin Injection
• 7.3 Patch-Based Insulin Delivery

8 Global Smart Insulin Delivery Devices Market, By Component

• 8.1 Insulin Delivery Devices
• 8.2 Sensors and Monitoring Components
• 8.3 Connectivity Modules
• 8.4 Mobile Applications
• 8.5 Cloud-Based Software Platforms
• 8.6 Data Analytics and Decision Support Software

9 Global Smart Insulin Delivery Devices Market, By Connectivity Type

• 9.1 Bluetooth Connectivity
• 9.2 Wi-Fi Connectivity
• 9.3 Cellular Connectivity
• 9.4 Near Field Communication (NFC)

10 Global Smart Insulin Delivery Devices Market, By Patient Type

• 10.1 Pediatric Patients
• 10.2 Adult Patients
• 10.3 Geriatric Patients

11 Global Smart Insulin Delivery Devices Market, By Distribution Channel

• 11.1 Hospital Pharmacies
• 11.2 Retail Pharmacies
• 11.3 Online Pharmacies
• 11.4 Direct-to-Consumer Channels

12 Global Smart Insulin Delivery Devices Market, By Application

• 12.1 Type 1 Diabetes Management
• 12.2 Type 2 Diabetes Management
• 12.3 Gestational Diabetes Management

13 Global Smart Insulin Delivery Devices Market, By End User

• 13.1 Hospitals and Clinics
• 13.2 Diabetes Care Centers
• 13.3 Home Healthcare Settings
• 13.4 Ambulatory Care Centers

14 Global Smart Insulin Delivery Devices Market, By Geography

• 14.1 North America
  • 14.1.1 United States
  • 14.1.2 Canada
  • 14.1.3 Mexico
• 14.2 Europe
  • 14.2.1 United Kingdom
  • 14.2.2 Germany
  • 14.2.3 France
  • 14.2.4 Italy
  • 14.2.5 Spain
  • 14.2.6 Netherlands
  • 14.2.7 Belgium
  • 14.2.8 Sweden
  • 14.2.9 Switzerland
  • 14.2.10 Poland
  • 14.2.11 Rest of Europe
• 14.3 Asia Pacific
  • 14.3.1 China
  • 14.3.2 Japan
  • 14.3.3 India
  • 14.3.4 South Korea
  • 14.3.5 Australia
  • 14.3.6 Indonesia
  • 14.3.7 Thailand
  • 14.3.8 Malaysia
  • 14.3.9 Singapore
  • 14.3.10 Vietnam
  • 14.3.11 Rest of Asia Pacific
• 14.4 South America
  • 14.4.1 Brazil
  • 14.4.2 Argentina
  • 14.4.3 Colombia
  • 14.4.4 Chile
  • 14.4.5 Peru
  • 14.4.6 Rest of South America
• 14.5 Rest of the World (RoW)
  • 14.5.1 Middle East
    • 14.5.1.1 Saudi Arabia
    • 14.5.1.2 United Arab Emirates
    • 14.5.1.3 Qatar
    • 14.5.1.4 Israel
    • 14.5.1.5 Rest of Middle East
  • 14.5.2 Africa
    • 14.5.2.1 South Africa
    • 14.5.2.2 Egypt
    • 14.5.2.3 Morocco
    • 14.5.2.4 Rest of Africa

15 Strategic Market Intelligence

• 15.1 Industry Value Network and Supply Chain Assessment
• 15.2 White-Space and Opportunity Mapping
• 15.3 Product Evolution and Market Life Cycle Analysis
• 15.4 Channel, Distributor, and Go-to-Market Assessment

16 Industry Developments and Strategic Initiatives

• 16.1 Mergers and Acquisitions
• 16.2 Partnerships, Alliances, and Joint Ventures
• 16.3 New Product Launches and Certifications
• 16.4 Capacity Expansion and Investments
• 16.5 Other Strategic Initiatives

17 Company Profiles

• 17.1 Medtronic plc
• 17.2 Insulet Corporation
• 17.3 Tandem Diabetes Care, Inc.
• 17.4 Dexcom, Inc.
• 17.5 Abbott Laboratories
• 17.6 F. Hoffmann-La Roche Ltd.
• 17.7 Ypsomed Holding AG
• 17.8 EOFlow Co., Ltd.
• 17.9 Bigfoot Biomedical, Inc.
• 17.10 Beta Bionics, Inc.
• 17.11 SOOIL Development Co., Ltd.
• 17.12 ViCentra B.V.
• 17.13 Medtronic Diabetes
• 17.14 Cellnovo Group SA (historical/legacy player)
• 17.15 Diabeloop S.A.S.
• 17.16 CamDiab Ltd.
• 17.17 A. Menarini Diagnostics S.r.l.
• 17.18 Nipro Corporation